Facile induction of immune tolerance by an interleukin-2–TGFβ surrogate agonist
Summary
This Nature study reports a designed bi-specific cytokine surrogate (TGM1–IL-2) that delivers IL-2 and a low-affinity TGFβ mimic in cis to the same IL-2R-expressing T cell. By AND-gating STAT5 and SMAD2/3 signalling, the fusion protein potently converts antigen-activated CD4+ T cells into FOXP3+ peripherally induced regulatory T cells (pTreg cells) in mice. The authors show conversion rates of up to ~80% for antigen-specific OT-II and 2D2 T cells in secondary lymphoid organs after antigen plus intraperitoneal administration.
Induced pTreg cells are functional, stable, enriched for RORγt+ effector-colonic features, and protect against OVA-driven allergy, food allergy, DSS colitis and MOG35–55-induced experimental autoimmune encephalomyelitis (EAE). Mechanistically, IL-2 signalling is required for optimal expansion, proliferation and effector maturation of the induced pTreg population: an IL-2 signalling-defective fusion (TGM1–IL-2(DN)) still induces FOXP3 but yields fewer, less suppressive and less protective pTreg cells. Transcriptomics (scRNA-seq) show coordinated IL-2 + TGFβ activation drives a distinct effector/RORγt+ pTreg programme and suppresses alternative CD4+ fates.
Key Points
- TGM1–IL-2 is a fusion of a low-affinity helminth-derived TGFβ mimic (TGM1 domains1–3) to IL-2 with an albumin tag for half-life; it preferentially activates both pSTAT5 and pSMAD2/3 in CD25+ CD4+ T cells.
- In vitro, TGM1–IL-2 shifts FOXP3 induction dose–response leftwards by ~2 logs versus TGM1 or combined TGM1+IL-2, producing highly suppressive pTreg cells.
- In vivo, antigen + TGM1–IL-2 converts up to ~80% of antigen-specific CD4+ T cells into FOXP3+ pTreg cells across lymphoid organs; many of these are RORγt+ and show colonic Treg signatures.
- Induced pTreg cells are phenotypically activated (CD25, ICOS, CTLA4, CD103, IL-10) and suppress allergic airway inflammation, food allergy and EAE in mouse models.
- IL-2 signalling is necessary for optimal proliferation, effector differentiation, IL-10/BLIMP1 expression and in vivo protective capacity; IL-2-deficient signalling fusion (DN) yields weaker protection.
- scRNA-seq identifies distinct pTreg clusters enriched for TGFβ and IL-2 gene programmes and a coordinated effector/RORγt+ pTreg transcriptional network (Rorc, Maf, Prdm1, Il10, Ctla4, migration genes).
- Therapeutic caveats: the TGM1 component is helminth-derived and could provoke anti-drug antibodies in humans; data are preclinical (mouse models) and further human-compatible engineering will be needed.
- Approach suggests a generalisable strategy: pairing targeted STAT programmes with TGFβ–SMAD signalling to reprogramme CD4+ lineage commitment antigen-specifically.
Why should I read this?
Short version: if you care about making immune tolerance work without global immunosuppression, this paper hands you a clever molecular trick. The team fused IL-2 to a TGFβ mimic so both signals hit the same T cell at once — and it reliably turns antigen-activated CD4s into stable, suppressive pTregs that stop allergy, gut inflammation and neuroautoimmunity in mice. It’s a neat, potentially translational idea worth a read if you work in Treg biology, autoimmunity or immune engineering.
Context and relevance
T reg therapies and low-dose IL-2 approaches are an active clinical area but face issues: transient expansion, lack of antigen specificity, tissue targeting and off-target effects of TGFβ. This study demonstrates an antigen-specific, cell-targeted strategy that combines the homeostatic/proliferative benefits of IL-2 with TGFβ-driven FOXP3 induction while minimising broad TGFβ exposure. The results matter for researchers developing antigen-specific tolerance, engineered cytokine therapeutics, and cell-reprogramming strategies. Key translational considerations include immunogenicity of the helminth-derived TGM1 motif and the gap from mouse models to human safety and PK/PD.